The Melville, N.Y.-based dental products giant set the record and distribution dates for the spinout, first announced last April. Covetrus is slated to trade on the NASDAQ exchange beginning with the record date of Jan. 17, with a distribution date of Feb. 4, at which point the merger is expected to close. Assuming that the federal government shutdown continues, trading in Covetrus is anticipated on a “when-issued” basis for Jan. 28 under the CVETV symbol, until “regular way” trading begins on the first business day after Feb. 4 using the CVET symbol, Schein said.
Each HSIC share is due to receive a 40% dividend in the spinout, the company said. The stock closed up 1.7% at $75.37 apiece yesterday; with roughly 152.4 million shares in play, the valuation on the Schein portion of the combined business would be $4.60 billion at that price.
The spinout also means a dual market for HSIC shares between Jan. 17 and Feb. 4, Schein added, with regular-way trading under its usual symbol and “ex-distribution” transactions under the HSICV tag that have no entitlement to the Covetrus distribution.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.